Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

208.23 +5.77 (+2.85%)
Streaming Delayed Price Updated: 12:53 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 728,303
Open 201.22
Bid (Size) 208.03 (1)
Ask (Size) 208.25 (4)
Prev. Close 202.46
Today's Range 199.10 - 208.64
52wk Range 189.44 - 319.76
Shares Outstanding 144,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser. 
Via Investor's Business Daily
These Analysts Revise Their Forecasts On Biogen After Q1 Results
Via Benzinga

Performance

YTD
-22.22%
-22.22%
1 Month
-1.79%
-1.79%
3 Month
-15.43%
-15.43%
6 Month
-13.63%
-13.63%
1 Year
-27.71%
-27.71%

More News

Read More
Meta Platforms To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Where Biogen Stands With Analysts
Via Benzinga
Looking Into Biogen's Recent Short Interest
Via Benzinga
Forecasting The Future: 18 Analyst Projections For Biogen
Via Benzinga
Why Biogen Stock Leaped Nearly 5% Higher Today
Via The Motley Fool
Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why
Via Benzinga
Exposures Product Safety
Treasury Yields Rise, Tesla Jumps On Cheaper Model Pledge, Yen Plummets To 34-Year Lows: What's Driving Markets Wednesday?
Via Benzinga
Topics Bonds
Exposures Debt Markets
Biogen (BIIB) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings
Via Benzinga
BIIB Stock Earnings: Biogen Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline?
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Nasdaq Futures Get A Lift From Tesla, Texas Instruments Earnings: Analyst Points To Key Catalyst For Boosting Rally
Via Benzinga
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Big-Name Stocks Near 52 Week Lows: Are They A Buy?
Via Talk Markets
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
Via Investor's Business Daily
Exposures Product Safety
Tuesday Talk: Big-Tech Under Attack
Via Talk Markets
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Via InvestorPlace
European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
Via Benzinga
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Big-Name Stocks Near 52-Week Lows: Are They A Buy?
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.